Lonza Group AG

Lonza Group AG is a Swiss-based multinational specializing in contract development and manufacturing for the pharmaceutical, biotechnology, and nutrition sectors. As one of the world’s largest contract development and manufacturing organizations (CDMOs), Lonza partners with both emerging biotech firms and major pharmaceutical companies to advance innovative therapies from early-stage development through to commercial-scale production. The company’s core offerings encompass integrated biologics, advanced synthesis, and specialized modalities, including expertise in mammalian and microbial biologics, small molecules, highly potent active pharmaceutical ingredients (APIs), as well as cutting-edge technologies like mRNA, bioconjugates, and cell and gene therapies. With a workforce of approximately 18,000 employees across more than 30 global sites, Lonza serves as a key enabler for the life sciences industry, helping to turn breakthrough scientific discoveries into life-saving and life-enhancing medicines. Its broad market reach and deep technological capabilities make it a pivotal player in advancing healthcare innovation and supporting the global supply chain for advanced pharmaceuticals and biologics.